Determination of Amifostine and WR1065 in Rat Plasma by CE with Amperometric Detection

A method based on capillary electrophoresis with amperometric detection (CE–AD) was developed for the determination of amifostine (a cytoprotective agent, WR2721) and 2-(3-aminopropylamino)ethanethiol) (WR1065, the active metabolite of WR2721) in rat plasma. The contents of WR1065 and amifostine were determined by measuring WR1065 in deproteinized rat plasma using CE–AD before and after it was incubated at 37 °C for 4 h in acidic solution, respectively. During the incubation, amifostine was quantitatively converted to WR1065. In addition, cysteine and uric acid in rat plasma were also determined simultaneously. The detection electrode was a 500 μm diameter platinum disc electrode at a detection potential of +1.0 V (vs. saturated calomel electrode). The analytes can be well separated within 9 min in a 50-cm-long fused-silica capillary at a separation voltage of 18 kV in a 100 mM phosphate buffer (pH 7.5). The relation between peak current and analyte concentration was linear over about 3 orders of magnitude with the limits of quantification (S/N = 3) ranging from 0.60 to 1.40 μM. The method has been validated. Satisfactory within-day and between-day precisions were obtained with relative standard deviations of ≤4.9 and ≤5.1 % for WR1065 and ≤5.0 and ≤5.3 % for amifostine, respectively. The within-day and between-day accuracy was in the range of 98.6–102.3 % and 95.7–97.2 % for WR1065 and 97.5–98.6 and 95.3–97.1 % for amifostine, respectively.     

Measurement of S-2-(3-Aminopropylamino)ethanethiol (WR1065) in Blood and Tissues

Abstract

A procedure for the analysis of blood and tissue specimens for WR1065, the dephosphorylated metabolite of the radioprotective drug WR2721, has been developed. The method includes the use of a perchloric acid/EDTA extraction step at 0°C followed by chromatographic analysis using a mercury/gold thin film electrochemical detection liquid chromatography system. The extraction technique was designed to assure the stability of both WR1065 and any WR2721 present in blood or tissues. Using the described chromatography conditions and an analog of WR1065, 3-(4-aminopropylamino)propanethiol (WR251833), as an internal standard the respective retention times of these two compounds are 6.2 and 8.3 minutes. Experiments showing the applicability of this method to pharmacokinetic studies of WR2721 and WR1065 and to investigation of the kinetics of WR2721 hydrolysis in biological fluids such as stomach juice are described.     

A Liquid Chromatographic Electrochemical Assay for S-2-(3-Aminopropylamino) Ethylphosphorothioate (WR2721) in Human Plasma

Abstract

A liquid chromatographic electrochemical method for the determination of the radioprotective drug WR2721 in human plasma has been developed. This method includes the use of a Hg/Au electrochemical detector for the direct measurement of WR2721 concentration. An analog of WR2721, S-3-{4-aminobutylamino} propylphosphorothioate (WR80855) is the internal standard. The retention times for WR2721 and WR80855 are approximately 4.5 and 9 minutes, respectively. WR1065, the free sulfhydryl metabolite of WR2721, is retained on the column under the described chromatographic conditions and therefore does not interefere with the determination of the parent drug. With modification of the mobile phase WR1065 is eluted from the column at a retention time of approximately 20 minutes. This method has good linearity, precision and accuracy, and is free from interference from endogenous plasma substances. Preliminary results showing the applicability of this method to human pharmacokinetic studies and to investigating the enzymatic hydrolysis of WR2721 are presented.     

Determination of WR-1065 and WR-33278 by liquid chromatography with electrochemical detection

A liquid chromatographic method using electrochemical detection is presented for measuring the thiol WR-1065 12-(3-aminopropylamino) ethanethiol] and its symmetrical disulfide WR-33278 [NH2(CH2)3NHCH2CH2S]2. WR- 1065 is the active, radioprotective drug derived from the phosphorothioate pro-drug WR-2721 (amifostine). External standard curves for both compounds were linear over the range of 40-200 pmol injected (r2 = 0.999 and 0.996 for the thiol and disulfide, respectively). The detection and quantitation limits for WR-1065 were 9 and 18 pmol, respectively, whereas the corresponding values for WR-33278 were 30 and 59 pmol, respectively. Within- and between-day determinations of measurement Vision and accuracy for both compounds validated the suitability of this assay method.     

Immobilization of aminothiols on poly(oxyethylene H‐phosphonate)s and poly(oxyethylene phosphate)s—An approach to polymeric protective agents for radiotherapy of cancer

This study describes the synthesis and characterization of polymer complexes constructed from the radioprotective agent S‐2(3‐aminopropylamino) ethylphosphorothioic acid dihydrate (amifostine or WR‐2721), applied in the radiation cancer treatment, and biodegradable poly(oxyethylene H‐phosphonate), poly(hydroxyoxyethylene phosphate), or poly(methyloxyethylene phosphate). The immobilization of another radioprotector, used in cancer radiotherapy, 1‐(3‐aminopropyl)aminoethanethiol (WR‐1065) on the same polymers is also achieved through a covalent bond (Atherton‐Todd reaction coupling), ionic bond, and physical complexation, respectively. The structure of the complexes formed is elucidated by ¹H‐ ¹³C‐, ³¹P NMR and FTIR spectroscopy. © 2007 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 45: 1349–1363, 2007     

HPLC Assay for S-2-(3-Aminopropylamino)ethyl Phosphorothioate (WR 2721) in Plasma

Abstract

A specific HPLC assay has been developed for determination of the radioprotective drug WR 2721. The method is based on precolumn derivatization of plasma with fluorescamine, separation with a C-18 cartridge and detection by fluorescence. An external standard was used for calibration, and values were adjusted based upon recovery of added ¹⁴C-labeled WR 2721. WR 2721 had a retention time of about 13 minutes using a mobile phase of acetonitrile/water (22:78), 0.01 M in dibutylammonium phosphate, at a flow rate of 2 mL/min. Sensitivity of the assay was characterized to 2 μg/mL, and detector response was linear over the range of 2 to 1100 μg/mL. The assay requires 90 μL of plasma and has a total chromatography time of about 45 minutes. 2-(3-Aminopropylamino)ethanethiol (WR 1065) and bis- [2- (3-aminopropylamino)ethyl]disulfide (WR 33278), metabolites of the drug, and a variety of primary amines were shown not to interfere with the assay. Suitability of this assay for pharmacokinetic studies was demonstrated in preliminary experiments with a beagle dog.     

RP-LC Determination and Pharmacokinetic Study of Ferulic Acid and Isoferulic Acid in Rat Plasma After Taking Traditional Chinese Medicinal-Preparation: Guanxinning Lyophilizer

A sensitive, simple, and accurate method for determination and pharmacokinetic study of ferulic acid and isoferulic acid in rat plasma was developed using a reversed-phase column liquid chromatographic (RP-LC) method with UV detection. Sample preparations were carried out by protein precipitation with the addition of methanol, followed by evaporation to dryness. The resultant residue was then reconstituted in mobile phase and injected into a Kromasil C₁₈ column (250 × 4.6 mm i.d. with 5 μm particle size). The mobile phase was methanol-1% formic acid (33:67, v/v). The calibration plots were linear over the range 5.780–5780 ng·mL^?1 for ferulic acid and 1.740–348.0 ng·mL^?1 for isoferulic acid. Mean recoveries were 85.1% and 91.1%, respectively. The relative standard deviations (RSDs) of within-day and between-day precision were not above 15% for both of the analytes. The limits of quantification were 5.780 ng·mL^?1 for ferulic acid and 1.740 ng·mL^?1 for isoferulic acid. This RP-LC method was used successfully in pharmacokinetic studies of ferulic acid and isoferulic acid in rat plasma after intravenous injection of Guanxinning Lyophilizer.     

RP-LC Determination and Pharmacokinetic Study of Ferulic Acid and Isoferulic Acid in Rat Plasma After Taking Traditional Chinese Medicinal-Preparation: Guanxinning Lyophilizer

A sensitive, simple, and accurate method for determination and pharmacokinetic study of ferulic acid and isoferulic acid in rat plasma was developed using a reversed-phase column liquid chromatographic (RP-LC) method with UV detection. Sample preparations were carried out by protein precipitation with the addition of methanol, followed by evaporation to dryness. The resultant residue was then reconstituted in mobile phase and injected into a Kromasil C₁₈ column (250 × 4.6 mm i.d. with 5 μm particle size). The mobile phase was methanol-1% formic acid (33:67, v/v). The calibration plots were linear over the range 5.780–5780 ng·mL⁻¹ for ferulic acid and 1.740–348.0 ng·mL⁻¹ for isoferulic acid. Mean recoveries were 85.1% and 91.1%, respectively. The relative standard deviations (RSDs) of within-day and between-day precision were not above 15% for both of the analytes. The limits of quantification were 5.780 ng·mL⁻¹ for ferulic acid and 1.740 ng·mL⁻¹ for isoferulic acid. This RP-LC method was used successfully in pharmacokinetic studies of ferulic acid and isoferulic acid in rat plasma after intravenous injection of Guanxinning Lyophilizer.

     

LC Analysis of JS38, a Novel Antineoplastic Medicine, in the Plasma, Urine, Bile, Feces, and Other Tissues of Rats

An RP-LC method has been developed for analysis of JS38 in the plasma, urine, bile, feces, and important tissues of rats. Chromatography was performed on a C₁₈ analytical column with 80:20 (%, v/v) acetonitrile–phosphate buffer (0.5% phosphoric acid and 0.3% TEA adjusted to pH 5.0) as mobile phase at a flow-rate of 1.0 mL min^?1. Eluted compounds were detected at 400 nm by ultraviolet diode-array detection (DAD). The method was validated for linearity, accuracy (recovery from biological matrixes such as plasma, urine, bile, feces, and important organs), repeatability (within-day and between-day precision), and stability. The results indicate that the method is suitable for pre-clinical pharmacokinetic study of JS38.     

Validation of a high-performance chromatographic method for determination of cefotaxime in biological samples

An analytical method for detecting and quantifying cefotaxime in plasma and several tissues is described. The method was developed and validated using plasma and tissues of rats. The samples were analyzed by reversed phase liquid chromatography (HPLC) with UV detection (254 nm). Calibration graphs showed a linear correlation (r > 0.999) over the concentration ranges of 0.5–200 μg/mL and 1.25–25 μg/g for plasma and tissues, respectively. The recovery of cefotaxime from plasma standards prepared at the concentrations of 25 μg/mL and 100 μg/mL was 98.5 ± 3.5% and 101.8 ± 2.2%, respectively. The recovery of cefotaxime from tissue standards of liver, fat and muscle, prepared at the concentration of 10 μg/g was: 89.8 ± 1.2% (liver), 103.9 ± 6.5% (fat) and 97.8 ± 2.1% (muscle). The detection (LOD) and quantitation (LOQ) limits for plasma samples were established at 0.11 μg/mL and 0.49 μg/mL, respectively. The values of these limits for tissues samples were approximately 2.5 times higher: 0.3 μg/g (LOD) and 1.25 μg/g (LOQ). For plasma samples, the deviation of the observed concentration from the nominal concentration was less than 5% and the coefficient of variation for within-day and between-day assays was less than 6% and 12%, respectively. The method was used in a pharmacokinetic study of cefotaxime in the rat and the mean values of the pharmacokinetic parameters are given.     

Development and Validation of an HPLC–UV Method for the Determination of Insulin in Rat Plasma: Application to Pharmacokinetic Study

A simple, sensitive high performance liquid chromatographic method with UV detection was developed and validated for determination of insulin in rat plasma, using methyl paraben as an internal standard. Insulin was extracted from plasma by a liquid–liquid extraction with a mixture of dichloromethane and n-hexane (1:1, v/v) followed by an acidic back extraction. Chromatographic separation was achieved isocratically with a Phenomenex® C₁₈ analytical column (150 × 4.6 mm ID, 5 μm) at ambient room temperature. The calibration curves were linear within a concentration range of 0.7–8.4 μg mL^?1 (r ² = 0.9994). The inter-day and intra-day accuracy and precision were ≤3.33 and ≤5.55%. The limit of detection (LOD) and limit of quantification (LOQ) were 0.35 and 0.7 μg mL^?1. The average recovery was 87.86% for insulin and 83.52% for methyl paraben. Insulin containing plasma samples were stable at ?20 °C for 7 days. Validated HPLC method was successfully applied to a pharmacokinetic study of insulin in streptozotocin induced diabetic rats.     

HPLC Determination of Xylazine in Equine Plasma by High Performance Liquid Chromatography

Abstract

A high performance liquid chromatographic (HPLC) method is described for the determination of xylazine in equine plasma. The drug and internal standard (pindolol) were separated on a 5 μm cyanopropyl-modified column (250 × 4.6 mm i.d.) using a buffer-acetonitrile mixture containing an ion pairing reagent. The drug and internal standard were isolated from plasma by liquid extraction into ethyl acetate. The method was validated over the concentration range 50–2000 ng/ml in plasma; the reproducibility, expressed as the mean co-efficient of variation was less than 5.0% for both between-day and within-day replicate determinations. The method was linear over the concentration range studied. No interferences were observed from endogenous plasma components and the limit of detection was 20 ng/ml. The method was successfully applied to the determination of xylazine in equine plasma in a crossover study design for pharmacokinetic measurements.     

On-line dialysis-SPE-CE of acidic drugs in biological samples

A fully automated method is presented for the determination of acidic drugs in urine and serum using on-line dialysis-solid-phase extraction (SPE)-capillary electrophoresis (CE) with UV detection. With non-steroidal anti-inflammatory drugs (NSAIDs) as test compounds, detection limits in the biological samples were 0.05-1.0 microgram ml-1. Calibration plots were linear over two orders of magnitude and the within-day and between-day repeatability were better than 10%. The CE capillary and SPE column were used for over 500 analyses; the dialysis membrane was replaced after 250 analyses. A general protocol for dialysis-SPE-CE which can be used for amphoteric and acidic drugs was devised. The present results show that this protocol has general validity and can be recommended for future work on other classes of drugs.     

Quantitative Determination of Microcystins in Rat Plasma by LC–ESI Tandem MS

A rapid and sensitive method was developed and validated for the determination of MCYST (microcystin)-RR, -LR, and [Dha⁷] MCYST-LR in rat plasma by liquid chromatography-tandem mass spectrometry. The analytes were extracted from rat plasma by protein precipitation, followed by solid-phase extraction. Liquid chromatography with electrospray ionization mass spectrometry, operating in selected reaction monitoring (SRM) mode, was used to quantify MCYST-RR, -LR, and [Dha⁷] MCYST-LR in rat plasma. The recoveries for each analyte in rat plasma ranged from 70.8 to 88.7%. The calibration curve was linear within the range from 0.005 to 1.25 μg mL^?1. The limit of detection were 1.4, 1.0, 0.6 ng mL^?1 for MCYST-RR, -LR, and [Dha⁷] MCYST-LR. The overall precision was determined on three different days. The values for within- and between-day precision in rat plasma were within 15%. This method was applied to the identification and quantification of microcystins in rat plasma with acute exposure of microcystins via intravenous injection.     

Determination of nalbuphine by high-performance liquid chromatography with electrochemical detection: application to clinical samples from postoperative patients

A rapid, selective and reproducible high-performance liquid chromatographic assay with electrochemical detection was developed for the determination of nalbuphine in human plasma. The method involves extraction with chloroform-isopropanol at pH 9.4, back-extraction into dilute phosphoric acid and reversed-phase chromatography on a microBondapak phenyl column. The recovery of nalbuphine and naltrexone (internal standard) was greater than 90%. Calibration curves were linear over a concentration range of 3-36 ng/ml with coefficients of variation, within-day or between-day, not exceeding 8% at any level. Although the limit of detection was 0.3 ng/ml based on a signal-to-noise ratio of 3, the reliable limit of quantitation was 1 ng/ml (coefficient of variation 12%) using 1 ml of plasma. The dual-electrode detector was operated in the screening mode of oxidation (electrode 1, 0.3 V and electrode 2, 0.6 V), providing a greater specificity and reducing background noise. This procedure was applied to a large number of clinical samples in an intravenous dose-range pharmacokinetic study in patients.     

Differentiation of Resina Draconis from Sanguis Draconis by CE

A simple, accurate method based on capillary electrophoresis with electrochemical detection (CE–ED) has been developed to determine loureirin A, loureirin B and dracorhodin for differentiation of Resina Draconis from Sanguis Draconis. The effects of some important factors such as acidity and concentration of running buffer, separation voltage, injection time, and applied potential on the CE–ED working electrode were investigated. Under the optimum conditions, the three analytes could be well separated within 30 min in a 75 cm capillary at a separation voltage of 14 kV in a 80 mmol L^?1 borate buffer (pH 9.24). The working electrode was a 300-μm-diameter carbon disc electrode positioned opposite the outlet of the capillary in a wall-jet configuration and was set at a potential of 0.90 V (vs. SCE). Excellent linearity was established over two orders of magnitude with detection limits (S/N = 3) ranging from 3 × 10^?7 g mL^?1 to 1 × 10^?6 g mL^?1 for all three analytes. The relative standard deviations of peak current and migration times of loureirin A, loureirin B and dracorhodin were 2.1, 1.7, 4.4 and 2.9, 2.8, 3.3% (n = 5), respectively. The recoveries of three constituents ranged from 98.8 to 101.8%. The methodology has been successfully applied to analyze and differentiate the actual samples with satisfactory assay results.     

Development and Validation of a Sensitive LC-MS/MS Method for the Simultaneous Analysis of Three-Tropane Alkaloids in Blood and Urine

A simple and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the simultaneous analysis of three tropane alkaloids in blood and urine. After 1 mL of a blood or urine sample was extracted using a liquid–liquid extraction method with ethyl acetate at pH 8 and homatropine as the internal standard, the tropane alkaloids were separated. An Allure PFP propyl column (50 mm × 2.1 mm, 5 µm) separated the tropane alkaloids using an acetonitrile-buffer solution (20 mmol/L ammonium acetate and 0.1% formic acid, pH 4) (70:30) as the mobile phase at a flow-rate of 0.2 mL/min in isocratic mode, with the LC-MS/MS in the positive ionization mode. For each compound, detection was related to two daughter ions (scopolamine: m/z 304.4 → 138.1 and 155.9; atropine: m/z 290.3 → 124.0 and 93.1; anisodamine: m/z 306.3 → 140.1 and 91.1; and homatropine: m/z 276.3 → 124.3 and 142.1). The tropane alkaloids exhibited excellent linearity in the range of 0.05–100 ng/mL in blood and 0.2–100 ng/mL in urine, with a limit of detection range from 0.02 to 0.05 ng/mL for biological materials. The extraction recoveries of atropine, scopolamine, and anisodamine were more than 53% in the blood and urine; the interday and intraday RSDs were less than 10%; the within-day and between-day accuracy were between ?9.8% and +8.8%. The present method is simple and rapid, as shown by its application to a clinical case. This method is useful for routine analysis of tropane alkaloids in cases of suspected tropane alkaloid poisoning.     

Determination of Methadone in Biological Samples Using Liquid Phase Microextraction with Back Extraction Combined with LC

Liquid phase microextraction with back extraction (LPME-BE) combined with liquid chromatography-ultra violet (LC-UV) was applied for the extraction and determination of methadone in biological fluids. At the optimized conditions, an enrichment factor of 386 and detection limit (LOD) of 0.2 μg L^?1 were obtained. The calibration curve was linear (r ² = 0.989) in the concentration range of 0.6–1,000 μg L^?1. Within-day relative standard deviation RSD (S/N = 3) and between-day RSD were 2.7 and 5.9%, respectively. The feasibility of the proposed method was evaluated by extraction and determination of methadone in plasma and urine samples and satisfactory results were obtained.     

Development of a New Pre-Derivatization LC Method for Analysis of Branched-Chain and Aromatic Amino Acids in Rat Plasma and to Monitor their Dynamic Variation as a Result of Acute Hepatic Injury

9,10-Anthraquinone-2-sulfonyl chloride, a new derivatization reagent with strong UV absorbance, has been used to develop a reversed-phase liquid chromatographic method for analysis of branched-chain and aromatic amino acids in rat plasma. Because the reagent has a sulfonyl chloride group it is highly reactive with primary and secondary amino groups and reaction is complete within 5 min at room temperature in phosphate–borate buffer (pH 8.41)–acetonitrile. The resulting adducts were separated on a C₁₈ column at 30 °C and detected at 254 nm. Good linearity was achieved over the concentration range 10–1,000 μmol L^?1 for each amino acid. Intra-day precision (relative standard deviation; RSD, %) and accuracy (bias, %) for all quality-control concentrations, were ≤8.9% and 16.0%, respectively. Inter-day precision and accuracy were ≤9.5% and 11.7%, respectively. The method was used for analysis of branched-chain and aromatic amino acids in the plasma of rats with hepatic injury induced by d-galactosamine.     

Simultaneous Determination of Neuroactive Amino Acids in Serum by CZE Coupled with Amperometric Detection

A quantitative determination of six neuroactive amino acids (NAAs) was performed by capillary zone electrophoresis with amperometric detection (CZE-AD). This CZE-AD method utilized two electrolytes: the borate solution flowing in a capillary has the NAAs-separation effects, and the sodium hydroxide (NaOH) solution filled in the detection reservoir for the amperometric analysis of NAAs. The following experimental parameters were optimized: the working electrode potential, the pH value, the component, and the concentration of running buffer, the separation voltage, and the injection time on CZE-AD. Then, under the optimum conditions, the six NAAs could be completely separated in 30 min and had well-shaped AD responses at 0.75 V (versus SCE) on a copper electrode. The linear calibration range of NAAs was from 5 × 10^?4 to 5 × 10^?6 mol L^?1 with the limits of detection (LODs) ranging from 10^?6 to 10^?7 mol L^?1 (signal-to-noise ratio = 3), and the relative standard deviations (RSDs) of the migration time and peak area were 0.45–0.55 and 3.8–6.3 %, respectively. Moreover, this method has succeeded in human serum analysis, and the determined contents of the six NAAs in human serum were in an average recovery range of 85.3–117.9 %, which confirmed the validity and practicability of this method.